(MedPage Today) — NEW ORLEANS — Loberamisal improved functional outcomes after acute ischemic stroke in a placebo-controlled phase III trial, raising its prospects as an investigational neuroprotective therapy.
In patients with relatively…
Source link : https://www.medpagetoday.com/meetingcoverage/isc/119779
Author :
Publish date : 2026-02-06 20:00:00
Copyright for syndicated content belongs to the linked Source.
